Previous studies showed the potential of vacuum-assisted biopsies (VABs) after NAST to identify patients with pCR for the omission of surgery.9,10 The aim of this study was to explore the feasibility of VAB after NAST to identify patients with HER2-positive breast cancer or TNBC and residual disease (ypT+ or ypN+), who might benefit from tailored, extended neoadjuvant treatment in future trials. The gene discussed is ERBB2; the disease is breast carcinoma.